

AHCL/ SE/ 41 /2020-21

November 12 2020

<b>The National Stock Exchange of India Limited</b> "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	<b>BSE Limited</b> Department of Corporate Services 1 <sup>st</sup> Floor, P.J. Towers, Dalal Street, Mumbai 400 001
<b>Symbol : AMRUTANJAN</b>	<b>Scrip Code: 590006</b>

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting**

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today (**November 12, 2020**) had inter-alia:

- (i) Approved the Un-audited Financial Results for the quarter and half year ended September 30, 2020. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared First Interim Dividend of Re.0.80/- per share for the financial year 2020-21 on the Equity Shares of the Company.

The Board Meeting commenced at 11.00 A.M. and concluded at ~~14~~ : 30 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited

**(M Srinivasan)**  
**Company Secretary & Compliance Officer**



**Encl:**

1. Un-audited Standalone Financials Results for the quarter and half year ended September 30 2020
2. Limited Review Report

**Amrutanjan Health Care Limited**

103, (Old No. 42-45), Luz Church Road,  
Mylapore, Chennai - 600 004  
Tamil Nadu, India.  
Tel : +91-44 - 2499 4465  
+91-44 - 2466 9000  
Fax : +91-44 - 2499 4585

E-mail : [customercare@amrutanjan.com](mailto:customercare@amrutanjan.com)  
Web Site : [www.amrutanjan.com](http://www.amrutanjan.com)  
Toll Free No. : 1 - 800 - 425 - 4545  
CIN - L24231TN1936PLC000017

**AMRUTANJAN HEALTH CARE LIMITED**

CIN No : L24231TN1936PLC000017

Registered Office: No. 103 (Old No. 42-45), Luz Church Road

Mylapore, Chennai - 600 004

**Statement of Unaudited Financial Results for the quarter and six months ended 30 September 2020**

*(Rs. in Lakhs)*

Particulars	Quarter ended			Period ended		Year ended
	30 September 2020 (Unaudited)	30 June 2020 (Unaudited)	30 September 2019 (Unaudited)	30 September 2020 (Unaudited)	30 September 2019 (Unaudited)	31 March 2020 (Audited)
<b>Income from operations</b>						
I Revenue from operations	9,211.17	4,661.85	7,480.77	13,873.02	11,940.36	26,147.67
II Other income	404.87	204.56	186.42	609.43	341.89	832.13
<b>III Total income (I + II)</b>	<b>9,616.04</b>	<b>4,866.41</b>	<b>7,667.19</b>	<b>14,482.45</b>	<b>12,282.25</b>	<b>26,979.80</b>
<b>IV Expenses</b>						
(a) Cost of materials consumed	2,592.95	694.79	2,427.56	3,287.74	4,111.60	8,805.65
(b) Purchases of stock-in-trade	1,371.40	467.53	1,103.91	1,838.93	1,933.53	3,598.92
(c) Changes in inventories of finished goods, work in progress and stock in trade	(141.24)	970.79	(136.13)	829.55	(208.20)	(697.45)
(d) Employee benefits expense	981.42	914.47	1,059.94	1,895.89	1,970.76	3,936.48
(e) Advertisement and selling expenditure	829.75	355.60	1,123.12	1,185.35	1,681.39	4,350.46
(f) Finance cost	4.52	4.48	5.03	9.00	10.22	22.10
(g) Depreciation and amortisation expense	88.75	94.81	126.66	183.56	211.61	435.94
(h) Other expenses	749.62	497.82	744.83	1,247.44	1,449.63	3,082.31
<b>Total expenses</b>	<b>6,477.17</b>	<b>4,000.29</b>	<b>6,454.92</b>	<b>10,477.46</b>	<b>11,160.54</b>	<b>23,534.41</b>
<b>V Profit before tax (III - IV)</b>	<b>3,138.87</b>	<b>866.12</b>	<b>1,212.27</b>	<b>4,004.99</b>	<b>1,121.71</b>	<b>3,445.39</b>
VI Tax expenses	783.99	223.40	371.93	1,007.39	351.85	937.06
<b>VII Profit for the period (V - VI)</b>	<b>2,354.88</b>	<b>642.72</b>	<b>840.34</b>	<b>2,997.60</b>	<b>769.86</b>	<b>2,508.33</b>
<b>VIII Other comprehensive income</b>						
Re-measurement (losses) / gain on defined benefit plans, net of taxes	16.62	(2.87)	(31.48)	13.75	(33.91)	(29.37)
<b>Total other comprehensive income/ (loss) for the period</b>	<b>16.62</b>	<b>(2.87)</b>	<b>(31.48)</b>	<b>13.75</b>	<b>(33.91)</b>	<b>(29.37)</b>
<b>IX Total comprehensive income for the period (VII + VIII)</b>	<b>2,371.50</b>	<b>639.85</b>	<b>808.86</b>	<b>3,011.35</b>	<b>735.95</b>	<b>2,478.96</b>
Paid-up equity share capital (Face value Re. 1/- each)	292.31	292.31	292.31	292.31	292.31	292.31
Other equity						15,650.25
Basic and diluted earnings per share	8.06 (not annualised)	2.20 (not annualised)	2.87 (not annualised)	10.25 (not annualised)	2.63 (not annualised)	8.58 (annualised)
<i>See accompanying notes to financial results</i>						

209



**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Note 1 - Statement of assets and liabilities**

		(Rs. in Lakhs)	
S. No.	Particulars	As at	As at
		30 September 2020	31 March 2020
		Unaudited	Audited
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	2,263.55	2,399.21
	(b) Right-of-use assets	140.08	158.26
	(c) Intangible assets	44.57	52.87
	(d) Financial assets		
	Investments	1,527.19	1,820.64
	Loans	46.31	47.03
	Other financial assets	2,572.32	2,712.32
	(e) Tax assets	120.27	120.27
	(f) Deferred tax assets (net)	504.95	439.97
	(g) Other non-current assets	141.61	201.92
	<b>Total non-current assets</b>	<b>7,360.85</b>	<b>7,952.49</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	1,344.02	2,371.59
	(b) Financial assets		
	Investments	325.63	-
	Trade receivables	1,207.82	2,646.36
	Cash and cash equivalents	1,590.58	722.06
	Other bank balances	8,074.27	2,910.79
	Other financial assets	4,184.01	3,301.11
	(c) Other current assets	441.63	630.12
	<b>Total current assets</b>	<b>17,167.96</b>	<b>12,582.03</b>
	<b>Total assets (1+2)</b>	<b>24,528.81</b>	<b>20,534.52</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	(a) Equity share capital	292.31	292.31
	(b) Other equity	18,661.60	15,650.25
	<b>Total equity</b>	<b>18,953.91</b>	<b>15,942.56</b>
<b>2</b>	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	(a) Financial liabilities		
	Lease liabilities	99.87	111.69
	Other financial liabilities	20.60	20.60
	(b) Provisions	605.59	553.40
	<b>Total non-current liabilities</b>	<b>726.06</b>	<b>685.69</b>
<b>3</b>	<b>Current liabilities</b>		
	(a) Financial liabilities		
	Lease liabilities	57.81	57.63
	Trade payables		
	total outstanding dues of micro, small and medium enterprises	139.76	88.28
	total outstanding dues of creditors other than micro, small and medium enterprises	3,309.49	3,045.97
	Other financial liabilities	99.12	252.29
	(b) Other current liabilities	474.66	246.03
	(c) Provisions	768.00	216.07
	<b>Total current liabilities</b>	<b>4,848.84</b>	<b>3,906.27</b>
	<b>Total equity and liabilities (1+2+3)</b>	<b>24,528.81</b>	<b>20,534.52</b>

22P



**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Note 2 - Statement of cash flows**

(Rs. in Lakhs)

Particulars	Period ended	Period ended	Year ended
	30 September 2020	30 September 2019	31 March 2020
	(Unaudited)	(Unaudited)	(Audited)
<b>Cash flow from operating activities</b>			
Profit before tax:	4,004.99	1,121.71	3,445.39
Adjustments for:			
Depreciation and amortisation	183.56	211.61	435.94
Loss allowance on trade receivables	113.00	62.00	241.00
Change in fair value of investments	(32.19)	15.86	(106.55)
Profit on sale of investments	-	(12.29)	-
Interest income on deposits with banks and financial institutions	(348.84)	(271.02)	(614.19)
Interest income on debt instruments	(37.32)	(37.32)	(43.04)
Excess provision written back, net	-	-	(14.99)
Finance costs	9.00	10.22	22.10
Unrealised (gain) on foreign exchange differences	(0.29)	(1.55)	(3.55)
<b>Operating profit before working capital / other changes</b>	<b>3,891.91</b>	<b>1,099.22</b>	<b>3,362.11</b>
Working capital adjustments:			
Decrease in trade receivables	1,325.73	823.31	409.54
Decrease / (increase) in non-current and current assets	248.80	(54.44)	(148.75)
Decrease in loans and other financial assets	8.60	4.69	1.91
Decrease / (increase) in inventories	1,027.57	(690.39)	(913.91)
Decrease in financial liabilities	(43.30)	(47.30)	(7.00)
Increase in provisions	46.83	43.40	31.02
Increase in trade payables	318.71	237.12	161.85
Increase in current liabilities	228.63	17.91	36.01
	<b>3,161.57</b>	<b>334.30</b>	<b>(429.33)</b>
<b>Cash generated from operating activities</b>	<b>7,053.48</b>	<b>1,433.52</b>	<b>2,932.78</b>
Less: Income tax paid (net)	(505.03)	(611.36)	(1,115.17)
<b>Net cash generated from operating activities (a)</b>	<b>6,548.45</b>	<b>822.16</b>	<b>1,817.61</b>
<b>Cash flow from investing activities</b>			
Payment for construction of property, plant and equipment and intangible assets (net)	(10.77)	(159.18)	(254.44)
Net investments made in bank deposits	(5,878.53)	(772.95)	(1,782.65)
Interest income received on deposits with banks and financial institutions	147.55	240.10	588.52
Interest income received on debt instruments	91.73	60.11	26.18
Purchase of investments	-	-	(388.04)
Redemption of investments	-	136.53	425.40
<b>Net cash used in investing activities (b)</b>	<b>(5,650.02)</b>	<b>(495.39)</b>	<b>(1,385.02)</b>
<b>Cash flow from financing activities</b>			
Dividend paid	-	(306.92)	(920.76)
Dividend distribution tax paid (DDT)	-	-	(189.27)
Interest paid	-	(0.11)	(2.60)
Payment of lease liabilities	(30.01)	(27.88)	(56.35)
<b>Net cash used in financing activities (c)</b>	<b>(30.01)</b>	<b>(334.91)</b>	<b>(1,168.98)</b>
<b>Net increase / (decrease) in cash and cash equivalents (a) + (b) + (c)</b>	<b>868.42</b>	<b>(8.14)</b>	<b>(736.39)</b>
Cash and cash equivalents at the beginning of the period/ year	722.06	1,458.55	1,458.55
Effect of exchange rate fluctuations on cash held	0.10	(0.69)	(0.10)
<b>Cash and cash equivalents at the end of the period/ year</b>	<b>1,590.58</b>	<b>1,449.72</b>	<b>722.06</b>
<b>Notes to cash flow statement</b>			
Components of cash and cash equivalents			
Cash on hand	3.92	3.39	4.42
Bank balances	1,586.66	175.16	117.64
Cheques on hand	-	1,271.17	-
Deposits	-	-	600.00
	<b>1,590.58</b>	<b>1,449.72</b>	<b>722.06</b>

209



**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
**Registered Office: No. 103 (Old No. 42-45), Luz Church Road**  
**Mylapore, Chennai - 600 004**

**Notes:**

3. The above financial results for the quarter and six months ended 30 September 2020 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 12 November 2020. The above results have been subjected to limited review by the statutory auditor of the Company. The auditors have issued an unmodified review report.

4. The financial results has been prepared in accordance with recognition and measurement principles laid down in accordance with the Indian Accounting Standard ('Ind AS'), 34 - "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations 2015.

5. **Segment reporting in the financial results:** Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

Particulars	Quarter ended			Period ended		Year ended
	30 September 2020 (Unaudited)	30 June 2020 (Unaudited)	30 September 2019 (Unaudited)	30 September 2020 (Unaudited)	30 September 2019 (Unaudited)	31 March 2020 (Audited)
<b>1 Segment revenue</b>						
a OTC Products	8,903.70	4,303.76	7,158.78	13,207.46	10,708.50	24,077.67
b Beverages	277.01	349.16	244.82	626.17	1,098.84	1,829.92
c Others	30.46	8.93	77.17	39.39	133.02	240.08
<b>Total</b>	<b>9,211.17</b>	<b>4,661.85</b>	<b>7,480.77</b>	<b>13,873.02</b>	<b>11,940.36</b>	<b>26,147.67</b>
<b>2 Segment results</b>						
a OTC Products	2,968.30	863.73	1,206.66	3,832.03	1,063.13	3,177.02
b Beverages	(150.55)	(75.22)	(90.57)	(225.77)	(81.99)	(156.22)
c Others	(25.50)	(37.42)	(36.89)	(62.92)	(70.71)	(191.06)
<b>Total</b>	<b>2,792.25</b>	<b>751.09</b>	<b>1,079.20</b>	<b>3,543.34</b>	<b>910.43</b>	<b>2,829.74</b>
Less :						
a) Finance cost	4.52	4.48	5.03	9.00	10.22	22.10
a) Other unallocable expenditure net of (unallocable income)	(351.14)	(119.51)	(138.10)	(470.65)	(221.50)	(637.75)
<b>Total profit before tax</b>	<b>3,138.87</b>	<b>866.12</b>	<b>1,212.27</b>	<b>4,004.99</b>	<b>1,121.71</b>	<b>3,445.39</b>
<b>3 Segment assets</b>						
a OTC Products	4,486.02	4,689.88	6,692.00	4,486.02	6,692.00	6,834.88
b Beverages	891.72	1,042.20	999.56	891.72	999.56	1,131.32
c Others	114.46	72.42	63.06	114.46	63.06	101.60
d Unallocated assets	19,036.61	14,454.00	12,151.44	19,036.61	12,151.44	12,466.72
<b>Total</b>	<b>24,528.81</b>	<b>20,258.50</b>	<b>19,906.06</b>	<b>24,528.81</b>	<b>19,906.06</b>	<b>20,534.52</b>
<b>4 Segment liabilities</b>						
a OTC Products	4,126.39	2,719.37	3,777.63	4,126.39	3,777.63	3,505.77
b Beverages	482.71	499.84	421.23	482.71	421.23	628.25
c Others	110.88	-	50.00	110.88	50.00	-
d Unallocated liabilities	854.92	456.88	717.63	854.92	717.63	457.94
<b>Total</b>	<b>5,574.90</b>	<b>3,676.09</b>	<b>4,966.49</b>	<b>5,574.90</b>	<b>4,966.49</b>	<b>4,591.96</b>
<b>Total capital employed in the Company</b>	<b>18,953.91</b>	<b>16,582.41</b>	<b>14,939.57</b>	<b>18,953.91</b>	<b>14,939.57</b>	<b>15,942.56</b>

6. The Company has elected to exercise the option permitted under section 115BAA of the Income tax Act, 1961, as introduced by the Taxation laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the half year ended September 30, 2019 and re-measured its deferred tax assets basis the rate prescribed in the said section. The impact of above mentioned change was recognised in the statement of profit and loss for the half year ended September 30, 2019 and for the year ended March 31, 2020.

7. In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption. The Company has considered internal and external information while finalizing various estimates in relation to its financial results captions upto the date of approval of the financial results by the Board of Directors. The actual impact of the global health pandemic may be different from that which has been estimated, as the COVID -19 situation evolves in India and globally. The Company will continue to closely monitor any material changes to future economic conditions.

For Amrutanjan Health Care Limited



S Sambhu Prasad  
Chairman & Managing Director

Date: 12 November 2020  
Place: Chennai

# B S R & Co. LLP

Chartered Accountants

KRM Tower, 1<sup>st</sup> & 2<sup>nd</sup> Floors,  
No.1, Harrington Road, Chetpet,  
Chennai – 600 031, India

Telephone + 91 44 4608 3100  
Fax. + 91 44 4608 3199


To  
Board of Directors of **Amrutanjan Health Care Limited**

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** for the quarter ended and year to date results for the period from 01 April 2020 to 30 September 2020 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **B S R & Co. LLP**

Chartered Accountants

Firm’s Registration No.: 101248W/W-100022

  
K Raghuram

Partner

Membership No.: 211171

UDIN: 20211171AAAACZ9465

Place: Chennai

Date: 12 November 2020

Registered Office